KKR & Flerie Form New Platform To Drive Specialized Pharma Services, Invest In Munich-Based Coriolis Pharma
Portfolio Pulse from Lekha Gupta
KKR & Co Inc and Flerie have formed a new global pharma services platform, Frontier Biosolutions, which will invest in companies focused on specialized pharmaceutical services. As an initial investment, the platform has invested in Munich-based Coriolis Pharma, a company involved in formulation research and development, analytical services, and non-GMP manufacturing of biologics and cell and gene therapy products. The investment is expected to drive Coriolis' expansion strategy in the cell and gene therapy segment and boost its range of global services.
October 16, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
KKR's formation of Frontier Biosolutions and investment in Coriolis Pharma could potentially boost its presence in the specialized pharmaceutical services sector. However, the company's shares closed lower by 1.71% at $60.25 on Friday.
The formation of Frontier Biosolutions and the investment in Coriolis Pharma could potentially open new revenue streams for KKR in the specialized pharmaceutical services sector. However, the immediate impact on the company's stock price is uncertain as the shares closed lower by 1.71% at $60.25 on Friday, indicating that the market may need more time to digest the news.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100